How to Get Wegovy: Obesity, Cardiovascular, and Pediatric Pathways

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• Wegovy has three FDA-approved indication pathways: obesity, cardiovascular disease with BMI 27+, and adolescent obesity
• The 2023 SELECT trial-based cardiovascular indication opened insurance coverage including Medicare that obesity-only Wegovy lacked
• Cash-pay brand Wegovy runs roughly $1,300-$1,400 per month; no Novo Nordisk LillyDirect-equivalent program exists
• Compounded semaglutide through 503A pharmacies offers a lower-cost alternative at $200-$500/month
• Adolescents 12-17 with severe obesity have a distinct pediatric pathway, but require specialist-led care

Direct answer

You can get Wegovy through three indication pathways and four access routes. Indication paths: obesity (BMI 30+ or 27+ with comorbidity), cardiovascular disease with BMI 27+, or pediatric obesity (ages 12-17 with BMI at or above the 95th percentile). Access routes: insurance with prior authorization, retail cash-pay around $1,300/month, Novo Cares patient assistance for qualifying low-income uninsured patients, or compounded semaglutide through 503A pharmacy. The 2023 cardiovascular indication expansion opened new coverage pathways including some Medicare coverage.

Table of contents

1. The three indication pathways
2. The four access routes
3. Path 1: insurance for obesity indication
4. Path 2: insurance for cardiovascular indication
5. Path 3: insurance for pediatric indication
6. Path 4: retail cash-pay
7. Path 5: Novo Cares patient assistance
8. Path 6: compounded semaglutide
9. How Wegovy differs from Ozempic in access
10. Common access barriers
11. Contrary view: should Novo Nordisk launch a direct-to-consumer program
12. Decision framework
13. FAQ
14. Sources

The three indication pathways

Wegovy carries three distinct FDA-approved indications, each with different qualifying criteria:

Indication	Criteria	Approval Date
Obesity	Adults BMI 30+, OR BMI 27+ with comorbidity	June 2021
Pediatric obesity	Ages 12-17 with BMI at or above the 95th percentile for age and sex; body weight greater than 60 kg	June 2023 (STEP TEENS)
Cardiovascular event reduction	Adults with established CVD and BMI 27+, regardless of diabetes	March 2024 (SELECT)

The cardiovascular indication is significant because it allowed Medicare coverage in some cases. Medicare Part D excludes drugs prescribed solely for weight loss, but cardiovascular event reduction is not weight loss in label terms; it is treatment of cardiovascular risk.

The four access routes

Route	Eligibility	Cost
Insurance	Match one of three indications + prior auth	Copay $25-$300/month
Retail cash-pay	Valid prescription	~$1,300-$1,400/month
Novo Cares	Uninsured, low-income, qualifying	$0 or reduced
Compounded semaglutide	Clinician-documented medical necessity	$200-$500/month

Path 1: insurance for obesity indication

The most common Wegovy access path. Steps:

1. Schedule with primary care, obesity medicine specialist, or telehealth provider
2. BMI calculation with documented height and weight
3. Comorbidity documentation if BMI 27-29.9 (labs, blood pressure, sleep study, etc.)
4. Document prior lifestyle intervention attempt (typically 3-6 months)
5. Provider submits prescription and prior authorization with documentation
6. Insurance approves or requests more information
7. Prescription routes to pharmacy
8. Pickup with copay

Common prior authorization requirements:

• Current BMI with measured height and weight (not patient-reported)
• ICD-10 obesity code (E66.x)
• Comorbidity ICD-10 codes if BMI 27-29.9
• Documented lifestyle intervention (clinic notes, dietitian visits, program participation)
• Sometimes: prior pharmacotherapy trial (phentermine, topiramate, etc.)
• Confirmation of no contraindications

Path 2: insurance for cardiovascular indication

The cardiovascular pathway is newer and less familiar to many prescribers. Criteria:

• Adult age 18+
• Established cardiovascular disease (prior MI, stroke, or symptomatic peripheral artery disease)
• BMI 27+ (overweight or obese)
• Diabetes is not required; if diabetes is present, this pathway still applies

Insurance prior authorization for the cardiovascular pathway typically requires:

• Documentation of cardiovascular event (MI, stroke, or PAD)
• Imaging or cardiology notes confirming the event
• Current BMI documentation
• Sometimes: documentation that the patient is on guideline-recommended cardiovascular therapy (statin, ACE inhibitor, etc.) before adding Wegovy

The SELECT trial (Lincoff et al. 2023, NEJM) supported this indication with a 20% reduction in MACE over a mean of 39.8 months. The trial enrolled 17,604 patients with BMI 27+ and established CVD without diabetes.

Medicare coverage under the cardiovascular pathway: Medicare Part D covers Wegovy when prescribed for cardiovascular event reduction in patients meeting criteria. Coverage requires the CVD diagnosis as the primary indication submitted.

Path 3: insurance for pediatric indication

Pediatric Wegovy was FDA-approved in June 2023 based on the STEP TEENS trial (Weghuber et al. 2022, NEJM), which showed 16.1% mean BMI reduction in adolescents aged 12-17 with obesity. Criteria:

• Adolescents aged 12-17
• BMI at or above the 95th percentile for age and sex (pediatric obesity definition)
• Body weight greater than 60 kg
• Used as adjunct to reduced-calorie diet and increased physical activity

Pediatric prescribing should occur through:

• Pediatric endocrinology
• Adolescent medicine
• Family medicine with adolescent obesity expertise
• Pediatric obesity programs at children's hospitals

Adult-focused telehealth platforms are not appropriate for adolescent care. Pediatric obesity management requires growth monitoring, puberty staging, family involvement, eating disorder screening, and coordination with the patient's pediatrician.

Path 4: retail cash-pay

Without insurance, brand Wegovy retails at approximately $1,300-$1,400 per month in 2026:

• CVS, Walgreens, Walmart: roughly $1,300-$1,400 per month
• Costco, Sam's Club (members): roughly $1,200-$1,350 per month
• Independent pharmacies: variable
• GoodRx and coupon programs: typically $1,200-$1,350 per month

Wegovy retail price is higher than brand Ozempic ($1,000-$1,200) because Wegovy is priced at the obesity-focused label with the higher dose ceiling. The active ingredient (semaglutide) is identical.

Novo Nordisk does not offer a direct-to-consumer cash-pay program for Wegovy comparable to Eli Lilly's LillyDirect for Zepbound. The closest equivalent is the manufacturer savings card, which requires commercial insurance to activate and reduces copays to $25-$150/month for eligible patients.

Path 5: Novo Cares patient assistance

The Novo Cares program provides medication at reduced or no cost to qualifying patients:

• U.S. residency
• Uninsured or with insurance that does not cover the medication
• Income below thresholds (typically 400% of federal poverty level, adjusted annually)
• Prescriber signature on application

Application process:

1. Complete the Novo Cares application form
2. Submit proof of income, residency, and insurance status
3. Foundation reviews and approves within 1-3 weeks typically
4. If approved, medication ships to prescriber or patient
5. Renewal required annually

Novo Cares is a meaningful option for uninsured patients with documented financial need who do not qualify for Medicaid. The paperwork is significant but the program has provided long-term medication access for patients who would otherwise be unable to afford treatment.

Path 6: compounded semaglutide

Compounded semaglutide is prepared by state-licensed 503A pharmacies in response to individual prescriptions. The February 2025 FDA declaration that the semaglutide shortage was resolved added restrictions on bulk-quantity compounding.

Current compounded semaglutide path:

1. Enroll through a platform partnering with a state-licensed 503A pharmacy
2. Clinician evaluates and documents medical necessity
3. Prescription routes to 503A pharmacy
4. Pharmacy prepares and ships medication
5. Ongoing clinical follow-up

Pricing typically $200-$500 per month. Compounded semaglutide is not FDA-approved and is not interchangeable with brand Wegovy or Ozempic.

How Wegovy differs from Ozempic in access

Wegovy and Ozempic contain identical semaglutide but differ in access realities:

Attribute	Wegovy	Ozempic
Primary indication	Obesity	Type 2 diabetes
Maximum dose	2.4 mg weekly	2 mg weekly
Cash-pay price	~$1,300-$1,400/month	~$1,000-$1,200/month
Insurance coverage	Obesity formulary; more variable	Diabetes formulary; more consistent
Off-label use	Cardiovascular without CVD (post-SELECT)	Weight loss without diabetes

Patients with type 2 diabetes typically pursue Ozempic. Patients with obesity, with or without cardiovascular disease, typically pursue Wegovy. Compounded semaglutide does not distinguish between brand labels.

Common access barriers

Coverage exclusions. Many commercial insurance plans exclude all obesity pharmacotherapy. Check your plan's benefit summary before pursuing prior authorization.

Step therapy. Some plans require prior trials of phentermine, topiramate, naltrexone-bupropion, or orlistat before approving Wegovy. Document past attempts.

BMI documentation gaps. Insurance requires measured BMI, not patient-reported. Make sure your clinical notes have current height and weight from a recent visit.

Comorbidity documentation gaps. If you have BMI 27-29.9, you must demonstrate a qualifying comorbidity. Lab results, blood pressure readings, ICD-10 codes, or specialist notes are needed.

Lifestyle intervention documentation. Plans often require 3-6 months of documented lifestyle attempt. Clinic notes, dietitian visits, or program participation can satisfy this.

Pediatric pathway access. Adolescent Wegovy requires specialist evaluation. General telehealth and adult primary care are not appropriate.

Contrary view: should Novo Nordisk launch a direct-to-consumer program

Eli Lilly's LillyDirect Self Pay Journey Program for Zepbound has created competitive pressure on Novo Nordisk. The argument for a Wegovy direct-to-consumer program:

• Patient demand exists; Wegovy has historically been supply-constrained
• LillyDirect captures market share Novo Nordisk loses to Zepbound
• Direct-to-consumer relationships enable better adherence support
• Reduces dependence on insurance coverage that varies dramatically by plan

Arguments against:

• Novo Nordisk has existing distribution partnerships with retail pharmacies that direct-to-consumer would disrupt
• Pricing pressure from direct-to-consumer may force broader price reductions across distribution
• Production capacity constraints may limit ability to serve direct-to-consumer demand

As of May 2026, Novo Nordisk has not launched a comparable program. The competitive pressure is real, but Novo Nordisk's strategy appears to be focused on insurance coverage expansion (cardiovascular pathway) and manufacturer savings cards rather than direct-to-consumer cash-pay.

Whether this changes in the future depends on LillyDirect's performance, Novo Nordisk's strategic priorities, and patient pressure for direct-to-consumer access.

Decision framework

You have BMI 30+ or 27+ with comorbidity, good insurance: Insurance pathway via obesity indication.

You have established cardiovascular disease and BMI 27+: Insurance pathway via cardiovascular indication. May qualify for Medicare coverage.

You are an adolescent 12-17 with severe obesity: Pediatric specialist or family medicine with adolescent obesity expertise. Not appropriate for adult-focused telehealth.

You meet criteria but no insurance coverage: Novo Cares for qualifying low-income patients, or compounded semaglutide as a lower-cost alternative.

You want the brand product, no insurance: Retail cash-pay at $1,300-$1,400/month, or pursue insurance coverage through prior authorization.

Boxed warning positive: Not eligible for Wegovy or any GLP-1 medication.

FAQ

How do I get Wegovy? Three indication pathways (obesity, cardiovascular, pediatric) and four access routes (insurance, cash-pay, Novo Cares, compounded).

Does insurance cover Wegovy? Varies by plan. Obesity coverage is plan-dependent; cardiovascular and pediatric pathways have expanded coverage including some Medicare.

How much does Wegovy cost without insurance? About $1,300-$1,400/month at retail. Compounded semaglutide runs $200-$500/month.

What is the cardiovascular pathway for Wegovy? Approved for adults with established CVD and BMI 27+, regardless of diabetes. Based on SELECT trial 2023.

Can adolescents get Wegovy? Yes, ages 12-17 with BMI at or above the 95th percentile. Specialist-led care.

Can I get Wegovy through telehealth? Yes for adults, in all 50 states with properly licensed providers.

What is Novo Cares? Novo Nordisk's patient assistance program for qualifying uninsured low-income patients.

How long does Wegovy prior authorization take? 24-72 hours typically; longer if step therapy or additional documentation is needed.

Sources

1. FDA. Wegovy Prescribing Information, including SELECT cardiovascular indication. Current revision 2025.
2. FDA. Wegovy Pediatric Approval Letter. June 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
5. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). NEJM. 2022.
6. Novo Nordisk. Novo Cares Patient Assistance Program: Eligibility and Application Process. 2025.
7. Novo Nordisk. Wegovy Manufacturer Savings Card: Terms and Eligibility. 2025.
8. Centers for Medicare and Medicaid Services. Medicare Part D Coverage of Wegovy for Cardiovascular Indication. 2025.
9. FDA. Drug Shortages: Semaglutide Shortage Resolution. February 2025.
10. American Academy of Pediatrics. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics. 2023.
11. Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2023 update.
12. State Boards of Pharmacy. 503A Compounding Regulations Survey. NABP, 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform connecting adult patients with independent licensed clinicians and U.S.-based pharmacies. We do not provide pediatric care. Adolescent patients require specialist evaluation outside our adult-focused scope.

Compounded Medication Notice. Compounded semaglutide is prepared by a state-licensed 503A pharmacy in response to an individual prescription. It is not FDA-approved and is not interchangeable with brand Wegovy or Ozempic. Formulations vary between compounding pharmacies.

Results Disclaimer. Pricing cited reflects approximate market rates as of May 2026 and may change. Trial outcomes (STEP 1, SELECT, STEP TEENS) reflect average results in trial populations. Individual outcomes vary based on adherence, baseline health, and concurrent therapy.

Trademark Notice. Wegovy, Ozempic, and Novo Cares are trademarks of Novo Nordisk A/S. Mounjaro, Zepbound, and LillyDirect are trademarks of Eli Lilly and Company. GoodRx is a registered trademark of GoodRx Holdings. FormBlends is not affiliated with these companies.